The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma

References

• Gruss JD, Hermann F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Ann Onco11996; 7 (Supp14): S19–26.
   Google Scholar
• Armitage RJ. Tumour necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994; 6: 407–13.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189–92.
   Google Scholar
• Ansieau S, Scheffrahn I, Mosialos G, et al. Tumour necrosis factor receptor-associated factor (TRAF-1), TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1996; 93: 14053–8.
   PubMed Web of Science ®Google Scholar
• Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. Semin Immunol 1998; 10: 435–42.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organisation Classification of Tumours: Pathology and Genetics of Tum-ours of Haematopoitic and Lymphoid Tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Gruss Hi, Pinto A, Duyster J, Poppema S, Herrman F. Hodgkin's disease: a tumour with disturbed immunological pathways. Immunol Today 1997; 18: 156–63.
   Web of Science ®Google Scholar
• O'Grady JT, Stewart S, Lowrey J, Howie SEM, Krajewski AS. CD40 expression in Hodgkin's disease. Am J Pathol 1994; 144: 21–6.
   PubMed Web of Science ®Google Scholar
• Mosialos G, Birkenbach M, Yalamanchilli R, et al. Epstein-Barr virus transforming protein LMP-1 engages signalling proteins for the tumour necrosis factor receptor family. Cell 1995; 80: 389–99.
   PubMed Web of Science ®Google Scholar
• Busch K, Bishop GA. The EBV transforming protein, latent membrane protein-1, mimics and cooperates with CD40 signalling in B lymphocytes. J Immunol 1999; 162: 2555–61.
   PubMed Web of Science ®Google Scholar
• Miettinen M. CD30 distribution: Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas. Arch Pathol Lab Med 1992; 116: 1197–201.
   PubMed Web of Science ®Google Scholar
• Peh SC, Kim LH, Thanaletchimy N, Chai SP. Spectrum of Lymphomas from Klang General Hospital. Malays J Pathol 2000; 2: 13–20.
   Google Scholar
• Benharroch D, Levy A, Prinsloo I, et al. Apoptotic index as a prognostic factor in Hodgkin's disease. Leuk lymphoma 1999; 33: 351–9.
   PubMed Web of Science ®Google Scholar
• Gruss Hi, Boiani N, Williams DE, et al. Pleiotropic effects of CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045–56.
   PubMed Web of Science ®Google Scholar
• Jarrett AF, Armstrong AA, Alexender E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996; 7(Suppl 4): S5–10.
   Google Scholar
• Croager E, Gout AM, Abraham Li. Involvement of Sp 1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000; 156: 1723–31.
   Google Scholar
• Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000; 156: 1479–84.
   PubMed Web of Science ®Google Scholar
• Mir SS, Richter BWM, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin's disease cells. Blood 2000; 98: 4307–12.
   Google Scholar
• Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30 + tumours. J Clin Oncol 1997; 15: 3355–62.
   PubMed Web of Science ®Google Scholar
• Kehry MR. CD40-mediated signalling in B-cells. J Immunol 1996; 156: 2345–8.
   PubMed Web of Science ®Google Scholar
• Kanzler H, Kupper R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumour clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184: 1495–505.
   PubMed Web of Science ®Google Scholar
• Bargou RC, Leng C, Krappmann D, et al. High level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340–7.
   PubMed Web of Science ®Google Scholar
• Gruss Hi, Hirschstein D, Wright B, et al. Expression and function of CD40 on Hodgkin's and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305–14.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg Cells and Hodgkin's disease cell lines. Blood 1995; 85: 780–9.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A. CD40: a sensitive marker of Reed-Sternberg cells. Blood 1996; 87: 4918–19.
   PubMed Web of Science ®Google Scholar
• Murray PG, Flavell JR, Baumforth KRN, et al. Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease. J Pathol 2001; 194: 158–64.
   PubMed Web of Science ®Google Scholar
• Hinz M, Loser P, Mathas S, et al. Constitutive NF-kB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of anti-apoptotic genes in Hodgkin's/Reed-Sternberg cells. Blood 2001; 97: 2798–807.
   PubMed Web of Science ®Google Scholar
• Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkBa gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395–401.
   PubMed Web of Science ®Google Scholar
• Vockerodt M, Haier B, Buttegereit P, Tesch H, Kube D. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/ SAPK2 pathway. Virology 2001; 280: 183–98.
   Google Scholar
• Kilger E, Kieser A, Baumann M, Hammerschidt W. Epstein-Barr virus mediated B-cell proliferation is dependent upon latent membrane protein-1, which simulates an activated CD40 receptor. EMBO J 1998; 17: 1700–9.
   PubMed Web of Science ®Google Scholar
• Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–56.
   PubMed Web of Science ®Google Scholar
• Moulian N, Berrih-Aknin S. Fas/Apo-1/CD95 in health and autoimmune disease: thymic and peripheral aspects. Semin Immunol 1998; 10: 449–56.
   PubMed Web of Science ®Google Scholar
• Metkar SS, Naresh KN, Redkar AA, et al. Expression of Fas and Fas ligand in Hodgkin's disease. Leuk Lymphoma 1999; 33: 521–30.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Harris NL, Ritz J, Robertson Mi. Expression of CD95 antigen and bc1-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996; 148: 847–53.
   PubMed Web of Science ®Google Scholar
• Xerri L, Carbuccia N, Parc P, Birg F. Frequent expression of Fas/ Apo-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 1995; 27: 235–41.
   PubMed Web of Science ®Google Scholar
• Gruss Hi, Dower SK. Tumour necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–404.
   PubMed Web of Science ®Google Scholar
• Dirks W, Schone S, Uphoff C, et al. Expression and function of CD95 (Fas/Apo-1) in leukaemia-lymphoma tumour lines. Br J Haenzatol 1997; 96: 584–93.
   PubMed Web of Science ®Google Scholar
• Kubonishi I, Daibata M, Sakuma I, et al. Expression of Fas and apoptosis of a Hodgkin's disease cell line (HD-70). Int J Hematol 1997; 65: 305–7.
   PubMed Web of Science ®Google Scholar
• Zhao S, Kliche KO, Clodi K, et al. Nodal T-lymphocytes of Hodgkin's disease have low expression of Fas ligand and CD30L which can be upregulated by IFN-alpha and CD3 antibody. Blood 1996; 88 (Suppl 1): 670a.
   Google Scholar
• Muschen M, Re D, Brauninger A, et al. Somatic mutation of the CD95 gene in Hodgkin's and Reed—Sternberg cells. Cancer Res 2000; 60: 5640–3.
   PubMed Web of Science ®Google Scholar
• Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622–30.
   PubMed Web of Science ®Google Scholar